New study tracks breast cancer treatments after drugs stop working
NCT ID NCT07407439
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This real-world study follows 245 people with HR+/HER2- advanced breast cancer who are taking CDK4/6 inhibitors combined with hormone therapy. Researchers want to see how long the treatment controls the cancer and what options work best after the cancer becomes resistant. The goal is to provide practical guidance for doctors treating patients in similar situations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib, dalpiciclib) combined with endocrine therapy
What this could lead to
If successful, this study could help doctors choose better treatments for patients whose cancer stops responding to CDK4/6 inhibitors.
What could go wrong
This is an observational study, not a controlled trial, so results may not apply to all patients. It only looks back at medical records from one hospital, which limits how widely the findings can be used.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Tianjin Medical University Cancer Insititute and Hospital
RECRUITINGTianjin, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••